The 2017 Biotech Stocks Recap


31-Dec-2017 13:12 PM



     The 2017 year has come to the end for U.S. stock market. This year, the leading sector of all was....(drum roll, please)... Spdr S&P Biotech Etf (XBI:NYSE) up 42.26% for the year, while the iShares Nasdaq Biotechnology ETF (IBB:NASDAQ) up 19.92%. Here is the blog for the other sector performance

     The notable big cap winners are:

  • Alnylam Pharmaceuticals Inc (ALNY) +233.82%
  • ILLumina Inc (ILMN) +69.74%
  • Vertext Pharmaceuticals Inc (VRTX) +101.32%

     Two of these winners are on our speculation buyout list ideas for 2018

     The small cap biotech etf, (XBI), up 42.26% for the year with the astronishing performance from these small cap biotech.

  • Marinus Pharmaceuticals Inc (MRNS) +877.25%
  • Madrigal Pharmaceuticals Inc (MDGL) +501.90% (It was small cap until their data out)
  • CymaBay Therapeutics Inc (CBAY) +425.71%

      Where there are winners, there has to be losers. Nobody like to talk about their losing trade. but frankly, losing trade will made you stronger and you learn a lot from it. These are the notable losers biotech of 2017:

  • Coherus BioSciences Inc (CHRS) -68.65%
  • Axovant Sciences Ltd (AXON) -57.22%
  • Intercept Pharmaceuticals Inc (ICPT) -46.54%

Will 2018 be a turnaround year for some of these biotech? stay tunes.

Contact us:

Twitter: @BiotechMoney18



Add Your Comment

Please select phase first
Disclaimer! This is NOT an investment advice. The data result herein is purely speculation only. You must do your own due diligence and mitigate your risk. You acknowledge that will not be held responsible and accountable for any losses you may incur using our Biotech Data Calculator. Please consult your own financial adviser before executing trades.